Apatinib

Phase 2UNKNOWN

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Biliary Tract Cancer

Conditions

Biliary Tract Cancer

Trial Timeline

Feb 22, 2017 → Mar 1, 2019

NCT ID

NCT03144856

About Apatinib

Apatinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Biliary Tract Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT03144856. Target conditions include Biliary Tract Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05029453	Approved	UNKNOWN	Aug 26, 2021	Mar 3, 2023	Gastric Cancer
NCT03709953	Phase 2	UNKNOWN	Oct 19, 2018	Apr 30, 2021	Lung Carcinoma
NCT03457467	Phase 2	UNKNOWN	Mar 15, 2018	Mar 15, 2020	Breast Cancer
NCT03521219	Phase 2	UNKNOWN	Feb 7, 2018	Nov 1, 2019	Intrahepatic Cholangiocarcinoma
NCT03390062	Phase 2	UNKNOWN	Jan 4, 2018	Aug 1, 2020	Glioma
NCT03403452	Phase 2	UNKNOWN	Jan 1, 2018	Dec 31, 2019	Colorectal Cancer
NCT03383237	Phase 2	UNKNOWN	Nov 29, 2017	Nov 1, 2019	Malignant Melanoma
NCT03376737	Phase 2	UNKNOWN	Oct 12, 2017	Jun 1, 2019	Lung Adenocarcinoma
NCT03251443	Phase 2	Completed	Aug 8, 2017	May 8, 2019	Intrahepatic Cholangiocarcinoma
NCT03190616	Phase 2	Completed	Jul 1, 2017	Dec 30, 2019	Colorectal Neoplasms
NCT03163381	Phase 2	UNKNOWN	Apr 11, 2017	Apr 11, 2019	Osteosarcoma, Advanced
NCT03180476	Phase 2	Completed	Apr 1, 2017	Apr 1, 2020	Nasopharyngeal Neoplasms
NCT03144856	Phase 2	UNKNOWN	Feb 22, 2017	Mar 1, 2019	Biliary Tract Cancer
NCT03170310	Phase 2	UNKNOWN	Feb 21, 2017	Sep 21, 2019	Advanced Esophagus Cancer
NCT02764268	Pre-clinical	Completed	Nov 2, 2016	Apr 15, 2019	Gastric Cancer
NCT02727309	Phase 1/2	UNKNOWN	Oct 1, 2015	Mar 1, 2019	Hepatocellular Carcinoma
NCT02509806	Phase 2/3	UNKNOWN	Jul 1, 2015	Dec 1, 2017	Gastric Cancer
NCT02510469	Phase 2/3	UNKNOWN	Jul 1, 2015	Jul 1, 2018	Gastric Cancer
NCT01653561	Phase 2	Completed	Nov 1, 2011	Oct 1, 2012	Breast Neoplasms
NCT01192971	Phase 2	Completed	Jun 1, 2010	Jul 1, 2013	Advanced Hepatocellular Carcinoma

Competing Products

20 competing products in Biliary Tract Cancer

See all competitors

Product	Company	Stage	Hype Score
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	52
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	52
Camrelizumab and Apatinib Plus GP	Sun Pharmaceutical	Phase 1/2	41
Recaticimab and Adebrelimab + GP chemotherapy	Sun Pharmaceutical	Phase 2	52
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)	Shionogi	Phase 2	52
E6011 + Placebo	Eisai	Phase 2	52
Lenvatinib	Eisai	Phase 2	52
gemcitabine + cisplatin	Eli Lilly	Phase 2	52
gemcitabine + cisplatin	Eli Lilly	Phase 2	52
Ramucirumab + Merestinib + Cisplatin + Gemcitabine + Placebo Oral + Placebo IV	Eli Lilly	Phase 2	52
Baricitinib + Placebo	Eli Lilly	Phase 2	52
Abemaciclib	Eli Lilly	Phase 2	52
SHR-A1811	Jiangsu Hengrui Medicine	Phase 2	52
SHR1258	Jiangsu Hengrui Medicine	Phase 2	52
SHR-1210+GEMOX	Jiangsu Hengrui Medicine	Phase 2	52
Rilvegostomig + Durvalumab + Gemcitabine/Cisplatin	AstraZeneca	Phase 3	77
Durvalumab + Gemcitabine + Cisplatin	AstraZeneca	Pre-clinical	23
durvalumab	AstraZeneca	Phase 3	77
gemcitabine + cisplatin + Placebo + cisplatin + cediranib + gemcitabine	AstraZeneca	Phase 2/3	65
mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)] + Durvalumab + Tremelimumab	AstraZeneca	Phase 1	33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved